{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:03:06Z","timestamp":1777449786639,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL085561-S"],"award-info":[{"award-number":["R01-HL085561-S"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL097047"],"award-info":[{"award-number":["R01-HL097047"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.amjmed.2020.02.040","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T19:43:32Z","timestamp":1586202212000},"page":"1187-1194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1016","volume":"133","author":[{"given":"Phillip H.","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gauravpal S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne C.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaywant","family":"Brar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherinne","family":"Arundel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven N.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Allman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-6424","authenticated-orcid":false,"given":"Ali","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.amjmed.2020.02.040_bib0001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2020.02.040_bib0002","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","article-title":"Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjmed.2020.02.040_bib0003","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjmed.2013.08.027","article-title":"Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure","volume":"127","author":"Ahmed","year":"2014","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.amjmed.2020.02.040_bib0004","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/clc.22889","article-title":"Digoxin use and lower risk of 30-day all-cause readmission in older patients with heart failure and reduced ejection fraction receiving beta-blockers","volume":"41","author":"Lam","year":"2018","journal-title":"Clin Cardiol"},{"issue":"11","key":"10.1016\/j.amjmed.2020.02.040_bib0005","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.amjmed.2019.05.012","article-title":"Digoxin use and outcomes in patients with heart failure with reduced ejection fraction","volume":"132","author":"Qamer","year":"2019","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2020.02.040_bib0006","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial","volume":"114","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.amjmed.2020.02.040_bib0007","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.amjcard.2008.05.068","article-title":"Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure","volume":"102","author":"Meyer","year":"2008","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2020.02.040_bib0008","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.amjmed.2013.08.006","article-title":"Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure","volume":"127","author":"Hashim","year":"2014","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2020.02.040_bib0009","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2004.03.004","article-title":"Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design","volume":"148","author":"Fonarow","year":"2004","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.amjmed.2020.02.040_bib0010","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.amjmed.2018.07.008","article-title":"Role of high-dose beta-blockers in patients with heart failure with preserved ejection fraction and elevated heart rate","volume":"131","author":"Lam","year":"2018","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2020.02.040_bib0011","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.amjmed.2018.09.011","article-title":"Spironolactone and outcomes in older patients with heart failure and reduced ejection fraction","volume":"132","author":"Bayoumi","year":"2019","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2020.02.040_bib0012","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ijcard.2011.10.089","article-title":"Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data","volume":"166","author":"Zhang","year":"2013","journal-title":"Int J Cardiol"},{"issue":"16","key":"10.1016\/j.amjmed.2020.02.040_bib0013","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"40","key":"10.1016\/j.amjmed.2020.02.040_bib0014","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/eurheartj\/ehz395","article-title":"Digoxin-mortality: randomized vs. observational comparison in the DIG trial","volume":"40","author":"Aguirre Davila","year":"2019","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.amjmed.2020.02.040_bib0015","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1016\/j.jacc.2019.09.047","article-title":"Reply: what is important for digoxin treatment in patients with heart failure","volume":"74","author":"Fonarow","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2020.02.040_bib0016","article-title":"The prevalent-user bias in observational studies and the importance of new-user design (letter to the editor)","author":"Ahmed","year":"2019","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.amjmed.2020.02.040_bib0017","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.amjmed.2020.02.040_bib0018","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.amjmed.2020.02.040_bib0019","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity score to help design observational studies: Application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"issue":"4","key":"10.1016\/j.amjmed.2020.02.040_bib0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjmed.2011.10.013","article-title":"Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease","volume":"125","author":"Ahmed","year":"2012","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2020.02.040_bib0021","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjmed.2012.06.031","article-title":"Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease","volume":"126","author":"Ahmed","year":"2013","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2020.02.040_bib0022","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjmed.2014.11.036","article-title":"Beta-blocker use and 30-day all-cause readmission in Medicare beneficiaries with systolic heart failure","volume":"128","author":"Bhatia","year":"2015","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2020.02.040_bib0023","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.amjmed.2013.01.004","article-title":"Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction","volume":"126","author":"Mujib","year":"2013","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.amjmed.2020.02.040_bib0024","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.amjmed.2016.05.008","article-title":"Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure","volume":"129","author":"Sanam","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2020.02.040_bib0025","unstructured":"GlaxoSmithKline. Lanoxin (digoxin) Tablets, USP prescribing information. Research Triangle Park, NC 27709; 2011."},{"issue":"1","key":"10.1016\/j.amjmed.2020.02.040_bib0026","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjcard.2008.06.068","article-title":"Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial","volume":"103","author":"Ahmed","year":"2009","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.amjmed.2020.02.040_bib0027","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/gerona\/62.3.323","article-title":"Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations","volume":"62","author":"Ahmed","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"10.1016\/j.amjmed.2020.02.040_bib0028","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(83)90346-7","article-title":"Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure","volume":"75","author":"Covit","year":"1983","journal-title":"Am J Med"},{"issue":"18","key":"10.1016\/j.amjmed.2020.02.040_bib0029","doi-asserted-by":"crossref","first-page":"24G","DOI":"10.1016\/0002-9149(92)91252-Y","article-title":"Digitalis and neurohormonal abnormalities in heart failure and implications for therapy","volume":"69","author":"Ferguson","year":"1992","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2020.02.040_bib0030","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1161\/01.CIR.84.5.2181","article-title":"Digoxin. A neurohormonal modulator in heart failure?","volume":"84","author":"Gheorghiade","year":"1991","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2020.02.040_bib0031","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0735-1097(89)90561-5","article-title":"Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure","volume":"13","author":"Gheorghiade","year":"1989","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2020.02.040_bib0032","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0167-5273(96)02776-3","article-title":"Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure","volume":"57","author":"Khoury","year":"1996","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2020.02.040_bib0033","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0735-1097(94)00417-O","article-title":"Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure","volume":"25","author":"Krum","year":"1995","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2020.02.040_bib0034","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0735-1097(97)00057-0","article-title":"Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?","volume":"29","author":"Slatton","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.amjmed.2020.02.040_bib0035","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1001\/jama.288.17.2144","article-title":"Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure","volume":"288","author":"Kitzman","year":"2002","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.amjmed.2020.02.040_bib0036","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.amjmed.2020.02.040_bib0037","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijcard.2014.03.005","article-title":"Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes","volume":"173","author":"Patel","year":"2014","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.amjmed.2020.02.040_bib0038","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/eurjhf\/hfs101","article-title":"Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study","volume":"14","author":"Patel","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.amjmed.2020.02.040_bib0039","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jchf.2012.08.001","article-title":"Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction","volume":"1","author":"Patel","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjmed.2020.02.040_bib0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2016.11.239","article-title":"The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: A meta-analysis of observational cohort and randomized controlled studies","volume":"228","author":"Fukuta","year":"2017","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2020.02.040_bib0041","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10741-014-9453-8","article-title":"Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis","volume":"20","author":"Bavishi","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"15","key":"10.1016\/j.amjmed.2020.02.040_bib0042","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934320302369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934320302369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:41:49Z","timestamp":1777380109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934320302369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0002934320302369"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2020.02.040","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2020.02.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}